(Update: Valneva’s commentary and Valneva stock resumption schedule)
PARIS (Agefi-Dow Jones)–The UK Medicines and Health Products Regulatory Agency (MHRA) announced on Thursday that it has approved biotech company Valneva’s Covid-19 vaccine.
The conditional marketing authorization granted by the MHRA is valid in Great Britain and Northern Ireland. It concerns the primary vaccination of adults aged 18 to 50, Valneva said in a press release.
“VLA2001 is the only inactivated whole virus Covid-19 vaccine approved in the UK and this approval could pave the way for the availability of an alternative vaccine solution for the UK population,” Valneva said.
“We believe this approval could also lead to new marketing authorizations in other regions of the world,” the group added.
The laboratory is still awaiting the green light from the European Union for its vaccine. Last month, the company said it was counting on receiving a positive opinion in April from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Suspended since Thursday at 9:00 a.m., the share price will resume at 1:30 p.m. that same day.
-Julien Marion and Franois Schott, Agefi-Dow Jones; +33 (0)1 41 27 47 94; [email protected] ed: VLV – DID
Agefi-Dow Jones The financial newswire
(END) Dow Jones Newswires
April 14, 2022 07:16 ET (11:16 GMT)